Therapy News and Research

RSS

FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.

2 Apr 2014

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation (NYSE: BSX) reported favorable results in studies related to cardiac resynchronization therapy (CRT), platinum chromium stent platforms and transcatheter aortic valve replacement (TAVR).

2 Apr 2014

RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial photodynamic therapy (I-PDT) to recurrent tumors of the head and neck.

2 Apr 2014

Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.

2 Apr 2014

Discovery could lead to new therapies for people with celiac disease

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder.

1 Apr 2014

Study of non-surgically implanted replacement pulmonary valve shows strong results

The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in patients with certain congenital heart defects, according to research presented by a U-M pediatric interventional cardiologist at the American College of Cardiology's 63rd Annual Scientific Session Sunday.

1 Apr 2014

NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration to market its Monarch eTNS System in Australia.

1 Apr 2014

DTI assessment indicates that mild hypothermia therapy may be beneficial for patients with diffuse axonal injury

Mild hypothermia has been shown to exert apparent neuroprotective effects in animal models of diffuse axonal injury. However, the clinical efficacy of mild hypothermia is controversial.

1 Apr 2014

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Adempas (riociguat) is available in the UK today as the first drug treatment for CTEPH, to treat adult patients with WHO Functional Class (FC) II to III with inoperable or persistent disease to improve exercise capacity.

1 Apr 2014

Scientists develop new substance that could simplify manufacture of cell therapy

Scientists at The University of Nottingham have developed a new substance which could simplify the manufacture of cell therapy in the pioneering world of regenerative medicine.

1 Apr 2014

Scientists develop new procedure using ultrasound energy to "ablate" prostate cancer

Men with prostate cancer face tough choices: when, or even if, to treat their cancer; what procedure to use; and how to balance their chosen treatment with their quality of life. Now, a new multicenter clinical trial seeks to offer men another option - one that physicians hope will treat prostate cancers with fewer side effects.

1 Apr 2014

Patients with autoimmune disease have 3.8-fold increased risk of developing epilepsy

Patients with an autoimmune disease have a 3.8-fold increased risk of developing epilepsy, according to a new population-level study from Boston Children's Hospital based on health insurance claim data.

1 Apr 2014

Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Gastric bypass and sleeve gastrectomy - two of the most commonly used bariatric surgeries - are more effective than intensive medical therapy alone when it comes to managing uncontrolled type 2 diabetes in overweight or obese patients after three years, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

Anti-anxiety drugs and sleeping pills have been linked to an increased risk of death, according to new research from the University of Warwick.

31 Mar 2014

Therapy News and Research

FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

Discovery could lead to new therapies for people with celiac disease

Study of non-surgically implanted replacement pulmonary valve shows strong results

NeuroSigma gets approval to market Monarch eTNS System in Australia

DTI assessment indicates that mild hypothermia therapy may be beneficial for patients with diffuse axonal injury

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Scientists develop new substance that could simplify manufacture of cell therapy

Scientists develop new procedure using ultrasound energy to "ablate" prostate cancer

Patients with autoimmune disease have 3.8-fold increased risk of developing epilepsy

Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Bariatric surgery patients report better quality of life

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News